Human methamphetamine pharmacokinetics simulated in the rat: Behavioral and neurochemical effects of a 72-h binge

Neuropsychopharmacology

Volumn 34, Issue 11, 2009, Pages 2430-2441

  Kuczenski, Ronald ^a   Segal, David S ^a   Melega, William P ^b   Lacan, Goran ^b   McCunney, Stanley J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Binge; Dopamine; Methamphetamine; Norepinephrine; Serotonin; Stereotypy

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; METHAMPHETAMINE; NORADRENALIN; SEROTONIN; TRITIUM; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BRAIN REGION; CAUDATE NUCLEUS; COHORT ANALYSIS; COMPUTER SIMULATION; CONTROLLED STUDY; DOPAMINE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EXPOSURE; FRONTAL CORTEX; HUMAN; LIGAND BINDING; LOCOMOTION; MALE; NEUROCHEMISTRY; NONHUMAN; NORADRENALIN BLOOD LEVEL; PLASMA HALF LIFE; PRIORITY JOURNAL; PUTAMEN; RAT; SEROTONIN BLOOD LEVEL; SPECIES DIFFERENCE; STEREOTYPY; TREATMENT DURATION;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; METHAMPHETAMINE; MOTOR ACTIVITY; NOREPINEPHRINE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SLEEP; TIME FACTORS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 70349104693     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.73     Document Type: Article

References (95)

1. Anggard E, Jonsson LE, Hogmark AL, Gunne LM (1973). Amphetamine metabolism in amphetamine psychosis. Clin Pharmacol Ther 14: 870-880
2. Angrist B (1987). Clinical effects of central nervous system stimulants: a selective update. In: Engel J, Oreland L (eds). Brain Reward Systems and Abuse. Raven Press: New York. pp 109-127.
3. Angrist B (1994a). Amphetamine psychosis: clinical variations of the syndrome. In: Cho AK, Segal DS (eds). Amphetamine and Its Analogues. Academic Press: San Diego. pp 387-414.
4. Angrist B (1994b). Psychosis-inducing effects of cocaine may show sensitization more than other effects. Neuropsychopharmacology 10 : 197S.
5. Ben Shahar O, Ahmed SH, Koob GF, Ettenberg A (2004). The transition from controlled to compulsive drug use is associated with a loss of sensitization. Brain Res 995: 46-54.
6. Boileau I, Rusjan P, Houle S, Wilkins D, Tong J, Selby P et al (2008). Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is VMAT2 a stable dopamine neuron biomarker? J Neurosci 28: 9850-9856.
7. Bowyer JF, Tank AW, Newport GD, Slikker Jr W, Ali SF, Holson RR (1992). The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels in rat striatum. J Pharmacol Exp Ther 260: 817-824.
8. Brady KT, Lydiard RB, Malcom R, Ballenger JC (1991). Cocaine-induced psychosis. J Clin Psychiatry 52: 509-512.
9. Buffenstein A, Heaster J, Ko P (1999). Chronic psychotic illness from methamphetamine. Am J Psychiatry 156: 662.
10. Cadet JL, Jayanthi S, Deng XL (2003). Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J 17: 1775-1788.
11. Cass WA, Manning MW (1999). Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine. J Neurosci 19: 7653-7660.
12. Cho AK, Melega WP, Kuczenski R, Segal DS (2001). Relevance of pharmacokinetic parameters in animal models of methamphe-tamine abuse. Synapse 39: 161-166.
13. Cook CE, Jeffcoat AR, Hill JM, Pugh DE, Patetta PK, Sadler BM et al (1993). Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphe-tamine hydrochloride. Drug Metab Dispos 21: 717-723.
14. Cook CE, Jeffcoat AR, Sadler BM, Hill JM, Voyksner RD, Pugh DE et al (1992). Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans. Drug Metab Dispos 20 : 856-862.
15. Costall B, Naylor RJ (1977). Mesolimbic and extrapyramidal sites for the mediation of stereotyped behavior patterns and hyperactivity by amphetamine and apomorphine in the rat. In: Ellinwood Jr EH, Kilbey MJ (eds). Cocaine and Other Stimulants. Plenum Press: New York. pp 47-76.
16. Davidson C, Gow AJ, Lee TH, Ellinwood Jr EH (2001). Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev 36: 1-22.
17. Davidson C, Lee TH, Ellinwood EH (2005). Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences. Neurochem Int 46 : 189-203.
18. Davis JM, Schlemmer Jr RF (1980). The amphetamine psychosis. In: Caldwell J (ed). Amphetamines and Related Stimulants: Chemical, Biological, Clinical and Social Aspects. CRC Press: Boca Raton, FL. pp 161-173.
19. Devoto P, Flore G, Pira L, Longu G, Gessa GL (2004). Alpha2-adrenoceptor mediated co-release of dopamine and noradrena-line from noradrenergic neurons' in the cerebral cortex. J Neurochem 88: 1003-1009.
20. Dickson PR, Lang CG, Hinton SC, Kelley AE (1994). Oral stereotypy induced by amphetamine microinjection into stria-tum: an anatomical mapping study. Neuroscience 61: 81-91.
21. Ferrario CR, Shoui M, Samaha A-N, Watson CJ, Kennedy RT, Robinson TE (2008). The rate of intravenous cocaine administration alters c-fos mRNA expression and the temporal dynamics of dopamine, but not glutamate, overflow in the striatum. Brain Res 1209: 151-156.
22. Fischman MW, Schuster CR (1974). Tolerance development to chronic methamphetamine intoxication in the rhesus monkey. Pharmac Biochem Behav 2: 503-508.
23. Fischman MW, Schuster CR, Javaid J, Hatano Y, Davis J (1985). Acute tolerance development to the cardiovascular and subjective effects of cocaine. J Pharmacol Exp Ther 235: 677-682.
24. Frey KA, Kilbourn MR, Robinson TE (1997). Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur J Pharmacol 334: 273-279.
25. Friedman SD, Castañeda E, Hodge GK (1998). Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induce neuro-toxicity. Pharmacol Biochem Behav 61: 35-44.
26. Gawin FH (1991). Cocaine addiction: psychology and neurophysiology. Science 251: 1580-1586.
27. Gawin FH, Khalsa ME (1996). Sensitization and 'street' stimulant addiction. In: Majewska MD (ed). Neurotoxicity and Neuropathology Associated with Stimulant Abuse. NIDA Research Monograph Series. U.S. Government Printing Office: Washington, DC. pp 224-250.
28. Gawin FH, Kleber HD (1986). Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Arch Gen Psychiatry 43: 107-113.
29. Ghitza UE, Fabbricatore AT, Prokopenko V, Pawlak AP, West MO (2003). Persistent cue-evoked activity of accumbens neurons after prolonged abstinence from self-administered cocaine. J Neurosci 23: 7239-7245.
30. Guilarte TR (2001). Is methamphetamine abuse a risk factor in parkinsonism? Neurotoxicology 22: 725-731.
31. Guilarte TR, Nihei MK, McGlothan JL, Howard AS (2003). Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity. Neuroscience 122: 499-513.
32. Harvey DC, Lacan G, Tanious SP, Melega WP (2000). Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res 871: 259-270.
33. Hogan KA, Staal RGW, Sonsalla PK (2000). Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J Neurochem 74: 2217-2220.
34. Jacobs EH, Smit AB, De Vries TJ, Schoffelmeer ANM (2003). Neuroadaptive effects of active versus passive drug administration in addiction research. Trends Pharmacol Sci 24: 566-573.
35. Jaffe JH (1995). Amphetamine (or amphetaminelike)-related disorders. In: Kaplan J (ed). Comprehensive Textbook of Psychiatry. Williams and Wilkins: Baltimore. pp 791-799.
36. Johnson RG, Carty SE, Hayflick S, Scarpa A (1982). Mechanism of accumulation of tyramine, metaraminol, and isoproterenol in isolated chromaffin granules. Biochem Pharmacol 31: 815-823.
37. Jones AW, Holmgren A, Kugelberg FC (2008). Driving under the influence of central stimulant amines: age and gender differences in concentrations of amphetamine, methamphetamine, and ecstasy in blood. J Stud Alcohol Drugs 69: 202-208. (Pubitemid 351878368)
38. Kalasinsky KS, Bosy TZ, Schmunk GA, Reiber G, Anthony RM, Furukawa Y et al (2001). Regional distribution of methamphe-tamine in autopsied brain of chronic human methamphetamine users. Forensic Sci Int 116: 163-169.
39. Kampman KM, Volpicelli JR, Alterman AI, Cornish J, O'Brien CP (2000). Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms. Am J Psychiatry 157: 2052-2054.
40. Kelly PH, Iversen SD (1976). Seclective 60HDA-induced destruction of mesolimbic dopamine neurons: abolition of psychosti-mulant-induced locomotor activities in rats. Eur J Pharmacol 40: 45-56.
41. Kelly PH, Seviour P, Iversen SD (1975). Amphetamine and apomor-phine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res 94: 507-522.
42. Kilbourn MR, Frey KA, Vander Borght TM, Sherman PS (1996). Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters. Nucl Med Biol 23: 467-471.
43. Kish SJ, Fitzmaurice PS, Boileau I, Schmunk GA, Ang LC, Furukawa Y et al (2008). Brain serotonin transporter in human methamphetamine users. Psychopharmacology 202: 649-661.
44. Kiyatkin EA, Brown PL (2004). Brain temperature fluctuations during passive vs. active cocaine administration: clues for understanding the pharmacological determination of drug-taking behavior. Brain Res 1005: 101-116.
45. Kramer JC (1972). Introduction to amphetamine abuse. In: Ellin-wood Jr EH, Cohen S (eds). Current Concepts on Amphetamine Abuse. U.S. Gov. Printing Office: Washington, DC. pp 177-184.
46. Kuczenski R, Segal DS (1997). An escalating dose-high dose binge pattern of amphetamine administration results in differential changes in the extracellular dopamine response profiles in caudate-putamen and nucleus accumbens. J Neurosci 17: 4441-4447.
47. Kuczenski R, Segal DS (1999a). Dynamic changes in sensitivity occur during the acute response to cocaine and methylpheni-date. Psychopharmacology 147: 96-103.
48. Kuczenski R, Segal DS (1999b). Sensitization of amphetamine-induced stereotyped behaviors during the acute response. J Pharmacol Exp Ther 288: 699-709.
49. Kuczenski R, Segal DS, Cho AK, Melega WP (1995). Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 15: 1308-1317.
50. Liu YJ, Peter D, Merickel A, Krantz D, Finn JP, Edwards RH (1995). A molecular analysis of vesicular amine transport. Behav Brain Res 73: 51-58.
51. Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA (1989). Cocaine receptors labeled by [3H]2b-carbomethoxy-3b-(4-fluorophenyl)tropane. Mol Pharmacol 36: 518-524.
52. Malberg JE, Seiden LS (1998). Small changes in ambient temperature cause large changes in 3,4-methylenedioxymetham-phetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18: 5086-5094.
53. McCann UD, Ricaurte GA (2004). Amphetamine neurotoxicity: accomplishments and remaining challenges. Neurosci Biobehav Rev 27: 821-826.
54. Melega WP, Cho AK, Harvey DC, Lacan G (2007). Methamphe-tamine blood concentrations in human abusers: application to pharmacokinetic modeling. Synapse 61: 216-220.
55. Melega WP, Raleigh MJ, Stout DB, Lacan G, Huang SC, Phelps ME (1997). Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res 766: 113-120.
56. Melega WP, Williams AE, Schmitz DA, DiStefano EW, Cho AK (1995). Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal. J Pharmacol Exp Ther 274: 90-96.
57. Myles BJ, Jarrett LA, Broom SL, Speaker HA, Sabol KE (2008). The effects of methamphetamine on core body temperature in the rat-PART 1: chronic treatment and ambient temperature. Psychopharmacology 198: 301-311.
58. Myles BJ, Sabol KE (2008). The effects of methamphetamine on core body temperature in the ratFpart 2: an escalating regimen. Psychopharmacology 198: 313-322.
59. Naudon L, Raisman-Vozari R, Edwards RH, Leroux-Nicollet I, Peter D, Liu Y et al (1996). Reserpine affects differentially the density of the vesicular monoamine transporter and dihydrote-trabenazine binding sites. Eur J Neurosci 8: 842-846.
60. Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB (2006). Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharma-col Exp Ther 319: 237-246.
61. Paulson PE, Camp DM, Robinson TE (1991). Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats. Psychopharmacology 103: 480-492.
62. Perez-Reyes M, White WR, McDonald SA, Hicks RE, Jeffcoat AR, Hill JM et al (1991). Clinical effects of daily methamphetamine administration. Clin Neuropharmacol 14: 352-358.
63. Peterson GL (1977). A simplification of the protein assay method of Lowry et al. which is more generally applicable. Analyt Biochem 83: 346-356.
64. Phillips JH (1982). Dynamic aspects of chromaffin granule structure. Neuroscience 7: 1595-1609.
65. Pickel VM, Chan J (1995). Use of quantitative ultrastructural immunoperoxidase labeling for analysis of catecholamine neurotoxicity and plasticity. Neurochem Int 26: 125-134.
66. Riviere GJ, Byrnes KA, Gentry WB, Owens SM (1999). Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. J Pharmacol Exp Ther 291: 1220-1226.
67. Samaha AN, Li YL, Robinson TE (2002). The rate of intravenous cocaine administration determines susceptibility to sensitization. J Neurosci 22: 3244-3250.
68. Samaha A-N, Mallet N, Ferguson SM, Gonon F, Robinson TE (2004). The rate of cocaine administration alters gene regulation and behavioral plasticity: implications for addiction. J Neurosci 24 : 6362-6370.
69. Satel SL, Southwick SM, Gawin FH (1991). Clinical features of cocaine-induced paranoia. Am J Psychiatry 148: 495-498.
70. Scherman D, Boschi G, Rips R, Henry J-P (1986). The regionaliza-tion of [3H]dihydrotetrabenazine binding sites in the mouse brain and its relationship to the distribution of monamines and their metabolites. Brain Res 370: 176-181.
71. Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y (1989). Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol 26: 551-557.
72. Scherman D, Jaudon P, Henry JP (1983). Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine. Proc Natl Acad Sci USA 80: 584-588.
73. Schmidt D, Roznoski M, Ebert MH (1990). Qualitative and quantitative high performance liquid chromatographic analysis of monoamine neurotransmitters and metabolites in cerebro-spinal fluid and brain tissue using reductive electrochemical detection. Biomedical Chromatography 4: 215-220.
74. Segal DS, Kuczenski R (1987). Individual differences in responsiveness to single and repeated amphetamine administration: behavioral characteristics and neurochemical correlates. J Pharmacol Exp Ther 242: 917-926.
75. Segal DS, Kuczenski R (1997a). An escalating dose 'binge' model of amphetamine psychosis: behavioral and neurochemical characteristics. J Neurosci 17: 2551-2566.
76. Segal DS, Kuczenski R (1997b). Repeated binge exposure to amphetamine and methamphetamine: behavioral and neuro-chemical characterization. J Pharmacol Exp Ther 282: 561-573.
77. Segal DS, Kuczenski R (2006). Human methamphetamine phar-macokinetics simulated in the rat: single daily intravenous administration reveals elements of sensitization and tolerance. Neuropsychopharmacology 31: 941-955.
78. Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK (2003). Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 28: 1730-1740.
79. Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK (2005). Prolonged exposure to intravenous methamphetamine: behavioral and neurochemical characterization. Psychopharmacology 180: 501-512.
80. Sherer MA (1988). Intravenous cocaine: psychiatric effects, biological mechanisms. Biol Psychiatry 24: 865-885.
81. Sherer MA, Kumor KM, Cone EJ, Jaffe JH (1988). Suspiciousness induced by four-hour intravenous infusions of cocaine. Arch Gen Psychiatry 45: 673-677.
82. Srisurapanont M, Jarusuraisin N, Jittiwutikan J (1999). Amphetamine withdrawal: II. A placebo-controlled, randomised, double-blind study of amineptine treatment. Aust N Z J Psychiatry 33: 94-98.
83. Stefanski R, Ladenheim B, Lee SH, Cadet JL, Goldberg SR (1999). Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of metham-phetamine. Eur J Pharmacol 371: 123-135.
84. Stuber GD, Roitman MF, Phillips PEM, Carelli RM, Wightman RM (2005). Rapid dopamine signaling in the nucleus accumbens during contingent and noncontingent cocaine administration. Neuropsychopharmacology 30: 853-863.
85. Sulzer D, Rayport S (1990). Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 5: 797-808.
86. Swerdlow NR, Vaccarino FJ, Amalric M, Koob GF (1986). The neural substrates for the motor-activating properties of psy-chostimulants: a review of recent findings. Pharmacol Biochem Behav 25: 233-248.
87. Vacca G, Ahn S, Phillips AG (2007). Effects of short-term abstinence from escalating doses of D-amphetamine on drug and sucrose-evoked dopamine efflux in the rat nucleus accumbens. Neuropsychopharmacology 32: 932-939.
88. Vander Borght TM, Kilbourn MR, Desmond T, Kuhl D, Frey K (1995). The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 294: 577-583.
89. Villemagne V, Yuan J, Wong DF, Dannals RF, Hatzidimitriou G, Mathews WB et al (1998). Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 18: 419-427.
90. Whishaw IQ, Fiorino D, Mittleman G, Castañeda E (1992). Do forebrain structures compete for behavioral expression? Evidence from amphetamine-induced behavior, microdialysis, and caudate-accumbens lesions in medial frontal cortex damaged rats. Brain Res 576: 1-11.
91. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM et al (1996a). Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nature Med 2: 699-703.
92. Wilson JM, Kish SJ (1996). The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 16: 3507-3510.
93. Wilson JM, Levey AI, Bergeron C, Kalasinsky KS, Ang L, Peretti F et al (1996b). Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 40: 428-439. (Pubitemid 26304800)
94. Winsauer PJ, Moerschbaecher JM, Molina PE, Roussell AM (2003). Contingent and concontingent cocaine administration in rhesus monkeys: a comparison of the effects on the acquisition and performance of response sequences. Behav Pharmacol 14: 295-306.
95. Yehuda S, Wurtman RJ (1972). The effects of D-amphetamine and related drugs on colonic temperatures of rats kept at various ambient temperatures. Life Sci 11: 851-859.